Modern approaches to the diagnosis and treatment of cardiogenic shock complicating acute myocardial infarction
https://doi.org/10.15829/1728-8800-2020-2661
Abstract
Cardiogenic shock (CS) is the most severe complication of myocardial infarction, manifested by an acute tissue hypoperfusion as a result of impaired contractile function of the heart. CS occupies a leading place in the patterns of mortality in patients with myocardial infarction, despite all the advances in medicine. This review presents a modern classification of CS and a risk assessment score, considers the main aspects of epidemiology and pathophysiology of CS, discusses issues of its diagnosis and treatment.
About the Authors
A. Yu. Serdechnaya
Altai Regional Cardiological Dispensary
Russian Federation
Barnaul
Russian Federation
Barnaul
I. A. Sukmanova
Altai Regional Cardiological Dispensary; Altai State Medical University
Russian Federation
Barnaul
Russian Federation
Barnaul
References
1. Shapovalov IN, Nikitina SYu, Ageeva LI, et al. Health Care in Russia 2019. Statistical compendium. Federal state statistics service (Rosstat). Moscow 2019, p. 169. (In Russ) ISBN: 978-5-89476-470-2.
2. Gerasimov AA, Polibin RV. Assessment of the attitude of cardiologists and therapists to clinical recommendations for the prevention and treatment of myocardial infarction. Preventive medicine. 2019;22(5):37-44. (In Russ.) doi:10.17116/profmed20192205137.
3. Thiele H, Allam B, Chatellier G, et al. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J. 2010;31:1828-35. doi:10.1093/eurheartj/ehq220.
4. Xiushui MR, Lenneman A. Cardiogenic Shock. 2019. https://emedicine.medscape.com/article/152191-overview 06,
5. Aissaoui N, Puymirat E, Tabone X, et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries. Eur Heart J. 2012;33:2535-43. doi:10.1093/eurheartj/ehs264.
6. Backhaus T, Fach A, Schmucker J, et al. Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction: results from the Bremen STEMI Registry. Clin Res Cardiol. 2018;107:371-9. doi:10.1007/s00392-017-1192-0.
7. Rathod KS, Koganti S, Iqbal MB, et al. Contemporary trends in cardiogenic shock: incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group. Eur Heart J Acute Cardiovasc Care. 2018;7:16-27 doi:10.1177/2048872617741735.
8. Xiushui MR, Lenneman A. Cardiogenic Shock Treatment & Management. 2019. https://emedicine.medscape.com/article/152191-treatment.
9. Jeger RV, Radovanovic D, Hunziker PR, et al. Ten-year incidence and treatment of cardiogenic shock. Ann Intern Med. 2008;149:618-26. doi: 10.7326/0003-4819-149-9-200811040-00005.
10. Poss J, Koster J, Fuernau G, et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. J Am Coll Card. 2017;69:1913-20. doi:10.1016/j.jacc.2017.02.027.
11. Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377:2419-32. doi:10.1056/NEJMoa1710261.
12. Burkhoff D, Garan AR, Kapur NK. The SCAI Cardiogenic Shock Staging System Gets Taken for a Test Drive. J Am Coll Cardiol. 2019;74(17):1-3. doi:10.1016/j.jacc.2019.08.1020.
13. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv. 2019;94:29-37 doI:10.1002/ccd.28329.
14. Auffret V, Cottin Y, Leurent G, et al. ORBI and RICO Working Groups. Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score. Eur Heart J. 2018;39:2090-102. doi:10.1093/eurheartj/ehy127
15. Boytsov SA, Akchurin RS, Pevzner DV, et al. Cardiogenic shock — the current state of the problem. Russian Journal of Cardiology. 2019;(10): 126-36. (In Russ.) doi: 10.15829/1560-4071-2019-10-126-136.
16. Ibanez B, James S, Agewall S, et al. The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Russian Journal of Cardiology. 2018;(5): 103-58. (In Russ.) doi: 10.15829/1560-4071-2018-5-103-158.
17. 17 Kadyrov TI. Classification of cardiogenic shock. (In Russ.) https://diseases.medelement.com/material/новая-классифика-ция-кардиогенного-шока-2019/822723231558534789
18. Harjola VP, Lassus J, Sionis A, et al. Clinicalpicture and risk prediction of short-term mortalityin cardiogenic shock. Eur J Heart Fail. 2015;17:501-9. doi:10.1002/ejhf.260.
19. ORBI Risk Score. https://www.orbiriskscore.com/
20. Alonso DR, Scheidt S, Post M, Killip T. Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation. 1973;48(3):588-96. doi:10.1161/01.cir.48.3.588.
21. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686-97 doi:10.1161/CIRCULATIONAHA.106.613596.
22. van Diepen S, Katz JN, Albert NM, et al, for the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement From the American Heart Association. Circulation. 2017; 136(16):e232-68. doi:10.1161/CIR.0000000000000525.
23. Neumann FJ, Sousa Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165. doi:10.1093/eurheartj/ehy394.
24. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271-306. doi:10.1089/dia.2012.0095.
25. Hochman JS, Sleeper LA, Godfrey E, et al. SHould We Emergently Revascularize Occluded Coronaries for Cardiogenic ShocK: An international randomized trial of emergency PTCA/CABG-trial design. Am Heart J. 1999;137(2):313-21. doi: 10.1053/hj.1999.v13795352.
26. Thiele H, Ohman EM, Desch S, et al. Management of cardiogenic shock. Eur Heart J. 2015;36:1223-30. doi:10.1093/eurheartj/ehv051.
27. 27 Kolte D, Sardar P, Khera S, et al. Culprit vessel-only versus multivessel percutaneous coronary intervention in patients with cardiogenic shock complicating ST-segment elevation myocardial infarction: a collaborative meta-analysis. Circulation Cardiovascular Intervention. 2017;10:005582. doi: 10.1161/CIRCINTERVENTIONS.117.005582.
28. Webb JG, Sanborn TA, Sleeper LA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J. 2001;141(6):964-70. doi:10.1067/mhj.2001.115294.
29. Thiele H, Zeymer U, Neumann F-J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287-96. doi:10.1056/NEJMoa1208410.
30. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-89. doi:10.1056/NEJMoa0907118.
31. Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018;72:173-82. doi:10.1097/00075198-200206000-00007.
32. Ponikowski PA, Voors AD, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;(1):7-81. (In Russ.) Ponikowski PA, Voors AD, Anker S, et al. doi:10.15829/1560-4071-2017-1-7-81.
33. Fuhrmann JT, Schmeisser A, Schulze MR, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36:2257-66. doi:10.1097/CCM.0b013e3181809846.
34. Belskaya LV, Gichkun OE, Gordeev ML, and others in the working group. National clinical recommendations “Heart transplantation and mechanical blood circulation support”/Professional Association: all-Russian public organization of transplantologists “Russian transplant society” 2016. р. 115. (In Russ). http://www.consultant.ru/document/cons_doc_LAW_333317
35. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2009;29(23):2909-45. doi:10.1093/eurheartj/sup013.
36. Ouweneel DM, Eriksen E, Sjauw KD, et al. Impella CP versus intra-aortic balloon pump support in acute myocardial infarction complicated by cardiogenic shock. The IMPRESS in Severe Shock trial. J Am Coll Card. 2017;69:278-87 doi:10.1161/CIRCINTERVENTIONS.116.004337
37. Thiele H, Jobs A, Ouweneel DM, et al Percutaneous shortterm active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J. 2017;38:3523-31. doi:10.1093/eurheartj/ehx363.
38. Ouweneel DM, Schotborgh JV, Limpens J, et al Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42:1922-34. doi:10.1007/s00134-016-4536-8.
39. Yannopoulos D, Bartos JA, Raveendran G, et al. Coronary artery disease in patients with out-of-hospital refractory ventricular fibrillation cardiac arrest. J Am Coll Card. 2017;70:1109-17 doi:10.1016/j.jacc.2017.06.059.
40. Suspitsyna IN, Sukmanova IA. Drug therapy in patients with acute coronary syndrome: target patient groups and drug therapy possibilities. Complex Issues of Cardiovascular Diseases. 2019;8(1):80-9. (In Russ.) doi:10.17802/2306-1278-2019-8-1-80-89.
Review
For citations:
Serdechnaya A.Yu., Sukmanova I.A. Modern approaches to the diagnosis and treatment of cardiogenic shock complicating acute myocardial infarction. Cardiovascular Therapy and Prevention. 2020;19(5):2661. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2661
Views:
4542
Email this article 
